Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...
News Medical on MSN2d
Affordability and supply remain critical to the success of long-lasting HIV drugAffordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
The Biden-Harris administration has a historic opportunity to help end HIV. New, cutting-edge drugs that prevent HIV are ...
Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...
Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...
Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...
Winnie Byanyima, from UNAIDS: ‘Lenacapavir is more effective than condoms or PrEP in prevention’
The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...
In the last 30 years, HIV rates have gone down, in large part because of the game-changing prescription drug pre-exposure ...
LGBTQ Nation on MSN1d
Biden administration adds injectable PrEP requirement for insurance providersPrEP, or pre-exposure prophylaxis, was first approved by the FDA in 2012 to prevent people exposed to HIV from becoming ...
Unlike oral PrEP treatments, which are taken daily, the drug is administered at six-month intervals and is the longest acting injectable produced to date. In a late-stage trial, lenacapavir reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback